Background Hereditary transthyretin (ATTRv) amyloidosis is a heterogeneous, progressive, multisystemic disease with a life-threatening course if left untreated. Given the current availability of effective therapies, close follow-up of presymptomatic TTR mutation carriers is essential to recognize disease onset at the earliest sign. In addition to routine techniques, in recent years several novel tools have been proposed, although a consensus on their use has not been reached yet. In this paper, we aimed to evaluate possible markers of neuropathic disease onset intended to discriminate clinically asymptomatic carriers from early symptomatic patients, thus allowing timely treatment initiation.Methods Thirty-eight presymptomatic carriers were enrolled. Clinical and electrophysiological findings at first evaluation and follow-up were collected. All carriers underwent an extensive clinical and instrumental evaluation according to the standard clinical practice. One or more non-routine investigations, whose use in this field is not yet validated (henceforth "unconventional"), were additionally assessed in a subgroup of individuals.Results Based on the exclusive use of routine investigations, it was possible to define disease onset in 4/38 carriers during the follow-up. Employing additionally one or more "unconventional" tests, abnormal findings, indicative of a possible "conversion" to symptomatic disease, were detected in further 12 cases. More than half of our study cohort showed findings suggestive of small nerve fiber (SF) involvement at either invasive or non-invasive tests.Conclusions A close, multidisciplinary monitoring of presymptomatic TTR mutation carriers is fundamental, and diagnostic workup should include both routine and "unconventional" tests. Assessment of SF involvement is important also in non-endemic countries.

Romano, A., Guglielmino, V., Bisogni, G., Di Paolantonio, A., Truini, A., Minnella, A. M., Sciarrone, M. A., Vitali, F., Maceroni, M., Galosi, E., Sabatelli, M., Luigetti, M., Early detection of nerve involvement in presymptomatic TTR mutation carriers: exploring potential markers of disease onset, <<NEUROLOGICAL SCIENCES>>, 2024; 45 (4): 1675-1684. [doi:10.1007/s10072-023-07177-x] [https://hdl.handle.net/10807/274987]

Early detection of nerve involvement in presymptomatic TTR mutation carriers: exploring potential markers of disease onset

Romano, Angela;Guglielmino, Valeria;Di Paolantonio, Andrea;Minnella, Angelo Maria;Sciarrone, Maria Ausilia;Vitali, Francesca;Maceroni, Martina;Sabatelli, Mario;Luigetti, Marco
2024

Abstract

Background Hereditary transthyretin (ATTRv) amyloidosis is a heterogeneous, progressive, multisystemic disease with a life-threatening course if left untreated. Given the current availability of effective therapies, close follow-up of presymptomatic TTR mutation carriers is essential to recognize disease onset at the earliest sign. In addition to routine techniques, in recent years several novel tools have been proposed, although a consensus on their use has not been reached yet. In this paper, we aimed to evaluate possible markers of neuropathic disease onset intended to discriminate clinically asymptomatic carriers from early symptomatic patients, thus allowing timely treatment initiation.Methods Thirty-eight presymptomatic carriers were enrolled. Clinical and electrophysiological findings at first evaluation and follow-up were collected. All carriers underwent an extensive clinical and instrumental evaluation according to the standard clinical practice. One or more non-routine investigations, whose use in this field is not yet validated (henceforth "unconventional"), were additionally assessed in a subgroup of individuals.Results Based on the exclusive use of routine investigations, it was possible to define disease onset in 4/38 carriers during the follow-up. Employing additionally one or more "unconventional" tests, abnormal findings, indicative of a possible "conversion" to symptomatic disease, were detected in further 12 cases. More than half of our study cohort showed findings suggestive of small nerve fiber (SF) involvement at either invasive or non-invasive tests.Conclusions A close, multidisciplinary monitoring of presymptomatic TTR mutation carriers is fundamental, and diagnostic workup should include both routine and "unconventional" tests. Assessment of SF involvement is important also in non-endemic countries.
2024
Inglese
Romano, A., Guglielmino, V., Bisogni, G., Di Paolantonio, A., Truini, A., Minnella, A. M., Sciarrone, M. A., Vitali, F., Maceroni, M., Galosi, E., Sabatelli, M., Luigetti, M., Early detection of nerve involvement in presymptomatic TTR mutation carriers: exploring potential markers of disease onset, <<NEUROLOGICAL SCIENCES>>, 2024; 45 (4): 1675-1684. [doi:10.1007/s10072-023-07177-x] [https://hdl.handle.net/10807/274987]
File in questo prodotto:
File Dimensione Formato  
2024 early detection.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 701.6 kB
Formato Adobe PDF
701.6 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/274987
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact